How Many Intercept Pharmaceuticals Inc (NASDAQ:ICPT)’s Analysts Are Bullish?

June 16, 2017 - By Marguerite Chambers

 How Many Intercept Pharmaceuticals Inc (NASDAQ:ICPT)'s Analysts Are Bullish?
Investors sentiment decreased to 0.99 in Q4 2016. Its down 0.23, from 1.22 in 2016Q3. It turned negative, as 37 investors sold Intercept Pharmaceuticals Inc shares while 38 reduced holdings. 19 funds opened positions while 55 raised stakes. 20.29 million shares or 0.16% more from 20.26 million shares in 2016Q3 were reported.
Advsr Asset Management Incorporated invested 0% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). 1,439 are held by Cam Grp A S. Great West Life Assurance Can holds 0% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 1,989 shares. First Republic Invest Management Inc accumulated 0% or 3,643 shares. Hudock Capital Ltd Liability Corp has 50 shares. Blackrock Fund Advsrs reported 0.01% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Manufacturers Life The, a Ontario – Canada-based fund reported 693 shares. 1492 Capital Management Limited Liability Company reported 2,043 shares stake. Fifth Third State Bank stated it has 0% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Polar Capital Llp has 33,500 shares. Bb Biotech Ag invested 1.03% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Principal Finance Incorporated owns 15,520 shares. 42,375 were accumulated by Ascend Capital Llc. 94,789 are held by Axa. Blackrock owns 2,969 shares or 0% of their US portfolio.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Ratings Coverage

Among 17 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 have Buy rating, 4 Sell and 4 Hold. Therefore 53% are positive. Intercept Pharmaceuticals had 28 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Buy” rating by Credit Suisse on Thursday, June 1. Vetr upgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Tuesday, September 22 to “Strong-Buy” rating. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Market Outperform” rating by JMP Securities on Tuesday, May 31. The firm earned “Underweight” rating on Thursday, August 13 by Morgan Stanley. The firm has “Underperform” rating by Morgan Stanley given on Friday, April 8. The firm earned “Market Perform” rating on Friday, December 4 by Wells Fargo. The firm has “Overweight” rating given on Wednesday, February 24 by Barclays Capital. Goldman Sachs initiated Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rating on Wednesday, March 30. Goldman Sachs has “Neutral” rating and $114 target. BMO Capital Markets initiated Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Thursday, April 7 with “Outperform” rating. The rating was downgraded by Laidlaw to “Sell” on Friday, August 5. Below is a list of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) latest ratings and price target changes.

01/06/2017 Broker: Credit Suisse Rating: Buy New Target: $201.0000 Maintain
20/01/2017 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade
30/12/2016 Broker: Wedbush Rating: Outperform New Target: $224 Maintain

About 84,433 shares traded. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since June 16, 2016 and is downtrending. It has underperformed by 31.22% the S&P500.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $2.87 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Another recent and important Intercept Pharmaceuticals Inc (NASDAQ:ICPT) news was published by Streetinsider.com which published an article titled: “Intercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial of OCA in …” on June 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.